259 related articles for article (PubMed ID: 38075413)
1. The role of long-acting antibiotics in the clinical practice: a narrative review.
Micheli G; Chiuchiarelli M; Taccari F; Fantoni M
Infez Med; 2023; 31(4):449-465. PubMed ID: 38075413
[TBL] [Abstract][Full Text] [Related]
2. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
Bassetti M; Labate L; Vena A; Giacobbe DR
Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
Zinzi D; Vlachaki I; Falla E; Mantopoulos T; Nathwani D
Eur J Health Econ; 2022 Nov; 23(8):1371-1381. PubMed ID: 35113269
[TBL] [Abstract][Full Text] [Related]
4. The current and future off-label uses of dalbavancin: a narrative review.
De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
[TBL] [Abstract][Full Text] [Related]
5. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
6. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
8. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
[TBL] [Abstract][Full Text] [Related]
9. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
10. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
[TBL] [Abstract][Full Text] [Related]
12. Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments.
Lupia T; De Benedetto I; Bosio R; Shbaklo N; De Rosa FG; Corcione S
Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109488
[TBL] [Abstract][Full Text] [Related]
13. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M; Andreoni M; Pea F; Viale P
Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis.
Thom H; Thompson JC; Scott DA; Halfpenny N; Sulham K; Corey GR
Curr Med Res Opin; 2015 Aug; 31(8):1539-51. PubMed ID: 26038985
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Use of Dalbavancin for Off-Label Indications.
Taylor K; Williamson J; Luther V; Stone T; Johnson J; Gruss Z; Russ-Friedman C; Ohl C; Beardsley J
Infect Dis Rep; 2022 Apr; 14(2):266-272. PubMed ID: 35447884
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
[TBL] [Abstract][Full Text] [Related]
17. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
[TBL] [Abstract][Full Text] [Related]
18. New agents approved for treatment of acute staphylococcal skin infections.
Tatarkiewicz J; Staniszewska A; Bujalska-Zadrożny M
Arch Med Sci; 2016 Dec; 12(6):1327-1336. PubMed ID: 27904526
[TBL] [Abstract][Full Text] [Related]
19. Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.
Deck DH; Jordan JM; Holland TL; Fan W; Wikler MA; Sulham KA; Ralph Corey G
Infect Dis Ther; 2016 Sep; 5(3):353-61. PubMed ID: 27370913
[TBL] [Abstract][Full Text] [Related]
20. Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center.
Brescini L; Della Martera F; Morroni G; Mazzanti S; Di Pietrantonio M; Mantini P; Candelaresi B; Pallotta F; Olivieri S; Iencinella V; Castelletti S; Cocci E; Polo RG; Veccia S; Cirioni O; Tavio M; Giacometti A
Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
